Portfolio News

 

   
September 3, 2015
Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering
DUBLIN and ALISO VIEJO, Calif., Sept. 3, 2015 /PRNewswire/ -- Allergan plc AGN, -0.45% a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

Read more

July 31, 2015
FDA Approval of ReShape™ Dual Balloon Marks Significant Step for the Weight Loss Program in Helping at Risk Group of Patients
Obesity is on the rise and is a worldwide epidemic. A recent Lancet study noted that the chance of an obese person becoming normal weight is less than .5%. Currently in the United States, the obese population outnumbers the overweight population. Bariatric surgery helps patients with severe obesity in terms of weight loss, reduction in severity and number of comorbid conditions. This week the U.S.

Read more

January 2014
AqueSys Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AqueSys, maker of proprietary implants for glaucoma-related vision loss, the world’s No. 2 cause of blindness as part of a $42m series D financing round.  ...

Read more

Team - David Guyer, David Milne
December 2013
CSA Medical
SV Life Sciences Fund V invested in CSA Medical, the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body, as part of a $16m financing round. ...

Read more

Team - Paul LaViolette, David Milne
November 2013
Cibiem Investment
SV Life Sciences notes that SV Life Science Fund V invested in Cibiem Inc. formerly Coridea NC1. Developer of CBM (Carotid Body Modulation) treatment of sympathetic nervous system-mediated diseases such as hypertension, heat failure, diabetes and renal failure as part of a $13m series B financing round. ...

Read more

Team - Paul LaViolette, David Milne
September 4, 2013
Transenterix merger with SafeStitch Medical (OTCBB: SFES)
SV Life Sciences Advisers notes that TransEnterix successfully merged with SafeStitch Medical on 4 September 2013. $30 Million Financing Raised from Existing TransEnterix and SafeStitch Medical Stockholders Combined Company to be Renamed TransEnterix MIAMI & RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--September 04, 2013 SafeStitch Medical, Inc. (OTCBB: SFES) and TransEnterix, Inc.

Read more

Team - Paul LaViolette, David Milne
March 2013
Cibiem Inc. (formerly Coridea NC1) Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Cibiem, focused on exploring possible treatments for diastolic heart failure, refractory angina and end-stage renal disease as part of a $10m series A financing round.  ...

Read more

Team - James Garvey, Eugene Hill, David Milne
June 2012
EBR Systems - Investment
SV Life Sciences Fund III invested in EBR Systems, developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure as part of a $8m bridge loan financing round.  ...

Read more

Team - James Garvey, David Milne
May 2012
Cibiem Inc. (formerly Coridea NC1) Investment
SV Life Sciences notes that SV Life Science Fund V invested in Cibiem Inc. formerly Coridea NC1. Developer of CBM (Carotid Body Modulation) treatment of sympathetic nervous system-mediated diseases such as hypertension, heat failure, diabetes and renal failure as part of a $10m financing round ...

Read more

Team - Paul LaViolette, David Milne
April 2012
AqueSys Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AqueSys, maker of proprietary implants for glaucoma-related vision loss, the world’s No. 2 cause of blindness as part of a $12m bridge round of funding. ...

Read more

Team - David Guyer, David Milne
December 15, 2011
CSA Medical Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in CSA Medical the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body as part of a £20.5m financing round. ...

Read more

Team - Paul LaViolette, David Milne
December 2011
TRANSENTERIX CLOSES $15M IN EQUITY FINANCING
Second tranche of Series B to accelerate development and commercialization of new flexible surgical tools SV Life Sciences notes that SV Life Sciences Fund IV invested in TransEnterix, maker of flexible medical devices that are changing how minimally invasive surgeries are performed today as part of a $15m Series B financing round. RESEARCH TRIANGLE PARK, N.C. – TransEnterix Inc. has closed $15 million in venture capital financing.

Read more

Team - Paul LaViolette, David Milne
November 2011
AcuFocus Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AcuFocus, maker of an innovative corneal Inlay to improve the treatment of new vision loss (presbyopia) as part of a $65m financing round. ...

Read more

Team - James Garvey, David Guyer
October 2011
Concentric Medical Exit
SV Life Sciences notes that in October 2011 – Stryker (NYSE:SYK) entered into a definitive agreement to acquire Concentric Medical for £135m in an all-cash transaction.  ...

Read more

Team - James Garvey, Greg Madden

⇧ Back to top